Evidence Intelligence™
- EvidenceScore™
- 81
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 5 studies
Add to Evidence TrackerPharmacological Treatments
Research Summary
Analyzed using Evidence Intelligence™
Dapagliflozin plus gliclazide combination improves blood sugar control in type 2 diabetes
Last updated June 11, 2026
Key finding
Combining dapagliflozin with gliclazide improves blood sugar control more than dapagliflozin alone in type 2 diabetes.
This 16-week study tested whether combining two diabetes medications works better than one alone. Researchers in India randomly assigned 244 adults with type 2 diabetes to receive either dapagliflozin plus gliclazide together, or dapagliflozin alone. All participants were already taking metformin but their blood sugar remained poorly controlled. The combination reduced HbA1c by 1.79% compared to 1.48% with dapagliflozin alone, a meaningful difference. Fasting and after-meal blood sugar also improved more with the combination. Only 5 patients taking the combination experienced low blood sugar events, and all recovered. The combination appears to help improve blood sugar control in people whose diabetes is not well-managed with metformin alone.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Randomized Controlled Trials (RCTs)
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Combining dapagliflozin with gliclazide improves blood sugar control more than dapagliflozin alone in type 2 diabetes.
Published in
Journal Reference
Publication details and source links for this paper.
Erande SG, Raykantiwar A, Shejole V, et al. A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. Cureus. 2026;18(2):e103676. doi:10.7759/cureus.103676
Main Effects
HbA1c → ↓ (moderate improvement, additional 0.3% reduction)
Fasting blood sugar → ↓ (moderate improvement)
After-meal blood sugar → ↓ (moderate improvement)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dapagliflozin, Dapagliflozin Gliclazide combination and HbA1c, Hypoglycemia events.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
- HbA1c
- Hypoglycemia events
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 50
2
Related topics
4
Evidence pairs
225
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Uses a randomized study design signal
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
SGLT2 Inhibitors and HbA1c
Related evidence
Evidence relationship
SGLT2 Inhibitors and Hypoglycemia
Save evidence
Evidence topic
HbA1c Reduction
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerHypoglycemia events
Dapagliflozin Gliclazide combination → Hypoglycemia events
Dapagliflozin Gliclazide combination → Hypoglycemia events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 55
- Slightly Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- The combination of dapagliflozin plus gliclazide appears to lower HbA1c more than dapagliflozin alone in people taking metformin
- Fasting and after-meal blood sugar levels also improved more with the combination
- Low blood sugar events were uncommon and not serious
Who this applies to
Adults aged 18-65 with type 2 diabetes whose blood sugar remains poorly controlled (HbA1c 8-10%) despite taking metformin at adequate doses for at least 3 months. Does not apply to people with reduced kidney function, type 1 diabetes, or very high blood sugar levels.
Keep in Mind
Study participants were from India only, so results may not fully apply to other populations
Between the Lines
- Short 16-week study period
- Open-label design (not blinded)
- Excluded people with kidney problems
- Conducted only in India
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Hypoglycemia.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 81
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 5 studies
View evidenceMedications
SGLT2 Inhibitors → Hypoglycemia
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
5 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
5 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Hypoglycemia Evidence Hub
All studies measuring Hypoglycemia
1 studies
outcome_hubMeasures Hypoglycemia as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dapagliflozin and HbA1c
Intervention: DapagliflozinOutcome: HbA1c
5 results
All studies on Dapagliflozin and Hypoglycemia events
Intervention: DapagliflozinOutcome: Hypoglycemia events
1 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
5 results
All studies measuring HbA1c
Outcome: HbA1c
5 results
All studies measuring Hypoglycemia events
Outcome: Hypoglycemia events
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve HbA1c?
Strong Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 80.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors affect hypoglycemia?
Moderate Evidence
SGLT2 Inhibitors may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Dapagliflozin Gliclazide combination improve HbA1c?
Emerging Evidence
Dapagliflozin Gliclazide combination appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Dapagliflozin Gliclazide combination affect hypoglycemia events?
Emerging Evidence
Dapagliflozin Gliclazide combination may improve Hypoglycemia events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Dapagliflozin improves metabolic outcomes in type 2 diabetes patientsDapagliflozin may improve RAAS markers in diabetes patientsDapagliflozin shows no long-term harm to bone health in women with diabetesDapagliflozin-linagliptin combo improves glycemic control and organ protectionDapagliflozin improves brain function in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.